"10.1371_journal.pone.0040443","plos one","2012-07-06T00:00:00Z","Ken Flanagan; Kent Fitzgerald; Jeanne Baker; Karin Regnstrom; Shyra Gardai; Frederique Bard; Simonetta Mocci; Pui Seto; Monica You; Catherine Larochelle; Alexandre Prat; Samuel Chow; Lauri Li; Chris Vandevert; Wagner Zago; Carlos Lorenzana; Christopher Nishioka; Jennifer Hoffman; Raquel Botelho; Christopher Willits; Kevin Tanaka; Jennifer Johnston; Ted Yednock","Elan Pharmaceuticals, San Francisco, California, United States of America; Neuroimmunology Research Laboratory, Center of Excellence in Neuromics, CRCHUM, Université de Montréal, Montréal, Quebec, Canada.","Conceived and designed the experiments: K. Flanagan K. Fitzgerald JB SG FB SM AP JJ TY. Performed the experiments: K. Flanagan KR PS MY CL SC LL CV WZ CL CN JH RB CW KT. Analyzed the data: K. Flanagan K. Fitzgerald JB KR JJ TY. Contributed reagents/materials/analysis tools: K. Fitzgerald PS MY. Wrote the paper: K. Flanagan JJ TY.","The following authors are paid employees of Elan Pharmaceuticals, who funded this study: Ken Flanagan, Kent Fitzgerald, Jeanne Baker, Karin Regnstrom, Shyra Gardai, Frederique Bard, Simonetta Mocci, Pui Seto, Monica You, Samuel Chow, Lauri Li, Chris Vandevert, Wagner Zago, Carlos Lorenzana, Christopher Nishioka, Jennifer Hoffman, Raquel Botelho, Christopher Willits, Kevin Tanaka, Jennifer Johnston, and Ted Yednock. Elan Pharmaceuticals has an interest in exploring the biology herein for development of a therapeutic antibody. There are no patents, other products in development or marketed products to declare. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2012","07","Ken Flanagan","KF",23,TRUE,1,1,1,1,TRUE,TRUE,TRUE,19,"3;5;6;7;8;9;10;11;12;13;14;15;16;17;18;19;20;22;23",TRUE
